-
Jan 8, 2025 | 
dailyreporter.esmo.org | Dario Trapani
Innovation in oncology is not a luxury, rather a necessity. Yet, it is not the mere presence of technology or novel therapies that defines true innovation, but the value they bring to patients and, by extent, to the society as a whole. If innovation does not tangibly improve lives or address inequities, it may be perceived just like a playful toy.
-
Oct 1, 2024 | 
dailyreporter.esmo.org | Dario Trapani
The development and approval of oncology medicines are multifaced processes which encompass patient needs and market dynamics to accelerate the accessibility to highly effective therapies while simultaneously ensuring a viable business model for the industry (JCO Glob Oncol. 2023 Sep:9:e2300294). Clinical trial populations often fail to accurately reflect the broader patient populations encountered in real-world settings — a discrepancy that has been long recognised (Lancet Reg Health Eur.
-
Aug 14, 2024 | 
dailyreporter.esmo.org | Dario Trapani
With a recent release, the International Agency for Research on Cancer (IARC), the specialised cancer agency of the World Health Organization (WHO), has portrayed the current landscape of cancer epidemiology worldwide (CA Cancer J Clin. 2024 May-Jun;74(3):229-263). Data reported a grim picture, with nearly 20 million new cancer cases, including nonmelanoma skin cancers, accompanied by 9.7 million deaths.
-
Jul 30, 2024 | 
ascopost.com | Dario Trapani
“Making a difference in global oncology means framing positive system changes. To me, Dr. Khalid El Bairi is among the global cancer researchers I know who so far has made the largest achievements. “Since the very first interaction with Khalid, what I have captured is passion for the community he serves and commitment to deliver real tangible impact for people.
-
Apr 2, 2024 | 
dailyreporter.esmo.org | Dario Trapani
This year World Health Organization (WHO)’s World Health Day (WHD) is centred around the theme “My health, my right”, aiming to “champion the right of everyone, everywhere to have access to quality health services”. With this claim, the WHD 2024 intends to highlight and accelerate progress toward the global response to sudden and abrupt changes of health conditions and health security which, in recent times, are becoming more common to the detriment of the lives of many.
-
Mar 14, 2024 | 
jamanetwork.com | Dario Trapani |Giuseppe Curigliano
The advent of antibody drug conjugates (ADCs) in cancer treatment raises fundamental questions, such as: does cancer antigen expression influence ADC efficacy? Precision in oncology with targeted agents has been commonly pursued through a perfect match of drugs and their targets. Yet, ADCs have inconstantly been developed based on this paradigm.
-
Dec 18, 2023 | 00339-6/abstract&sz=64)
jclinepi.com | Thomas Piggott |Lorenzo Moja |Kristina Jenei |Tamara Kredo |Nicole Skoetz |Rita Banzi | +10 more
Introduction Guidelines and essential medicine lists (EMLs) bear similarities and differences in the process that lead to decisions. Access to essential medicines is central to achieve to universal health coverage. The World Health Organization (WHO) EML has guided prioritization of essential medicines globally for nearly 50 years, and national EMLs (NEMLs) exist in over 130 countries. Guideline and EML decisions, at WHO or national levels, are not always coordinated and aligned.
-
Nov 21, 2023 | 
dailyreporter.esmo.org | Dario Trapani
The World Health Organization (WHO) has defined the social determinants of health (SDH) as “non-medical factors that influence health outcomes,” that include “conditions in which people are born, grow, work, live, and age, and the wider set of forces and systems shaping the conditions of daily life.” In oncology, SDH include economic policies and systems, political commitment and their outputs, social norms – ultimately representing the system-wide force capable of shaping the conditions...
-
Mar 8, 2023 | 
dailyreporter.esmo.org | Dario Trapani
Dose finding is the core of drug development, setting the stage for efficacy by ensuring safety first. The higher the dose, the more toxic the treatment, it is said, and many early-phase trials have been historically driven by finding the dose that is maximally tolerated by patients, often regardless of the anticancer activity demonstrated (J Natl Cancer Inst. 2009 May 20; 101(10): 708–720).
-
Jan 30, 2023 | 
ascopubs.org | Dario Trapani
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches.
